Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Primary Immune Thrombocytopenia
NCT04225156Phase 3Completed
- Sponsor
- argenx
- Start
- Jun 2020
- Primary completion
- Mar 2026
- Modality
- Antibody Fragments
- Countries
- 18
01
Overview
A Phase 3 trial of efgartigimod alfa in primary immune thrombocytopenia (ITP), sponsored by argenx. Started Jun 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04225156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225156.